Biotech scandal drags on as the feds only score partial victory against execs charged with cooking the books

More than three years after the SEC first charged former executives of Osiris Therapeutics for cooking the books, the legal saga still isn’t over just yet.

The feds had sought partial summary judgment — which would allow them to skip trial and go straight into a verdict — against Lode Debrabandere and Philip Jacoby, who held the CEO and CFO posts, respectively. While a Maryland judge mostly sided with them, he ruled that the SEC has not gone far enough to prove all the claims.